Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel

Inclusion Criteria: * Men or women at least 18 years of age at time of screening * Chronic plaque-type psoriasis diagnosed for at least 6 months before baseline * Moderate to severe psoriasis as defined at baseline by: * PASI score of 10 or greater and, * Investigator´s Global Assessment score of 3 or greater (based on a scale of 0 - 4) and, * Body Surface Area affected by plaque-type psoriasis of 10% or greater * Chronic plaque-type psoriasis patients who have previously received phototherapy or systemic psoriasis therapy at least once or who are candidates for such therapies in the opinion of the investigator. Exclusion Criteria: * Forms of psoriasis other than chronic plaque-type * Drug-induced psoriasis * Ongoing use of prohibited treatments * Previous exposure to etanercept * Active ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of treatment with etanercept Other In-/Exclusion criteria may apply